While early studies identified obesity, hyperandrogenemia and high levels of serum anti-Müllerian hormone as predictors for non-response [34,35,37,38,39], polymorphisms of CYP2D6 were additionally identified to alter drug disposition and response [5,14,36]. The gene discussed is CYP2D6; the disease is obesity due to melanocortin 4 receptor deficiency.